Literature DB >> 11061780

Blood-brain phenylalanine relationships in persons with phenylketonuria.

R Koch1, R Moats, F Guttler, P Guldberg, M Nelson.   

Abstract

OBJECTIVES: Clinicians caring for persons with phenylketonuria (PKU) have been perplexed by the occasional normal individual with the classical biochemical profile consistent with the diagnosis of PKU. Usually untreated subjects with the biochemical profile of blood phenylalanine (Phe) levels >1200 micromol/L are severely mentally retarded and may have neurological findings. Preliminary reports have recently appeared suggesting that low brain Phe levels, in comparison with elevated blood Phe levels, account for the occurrence of these occasional unaffected individuals with the biochemical profile consistent with PKU.
METHOD: Magnetic resonance imaging/magnetic resonance spectroscopy was used to measure brain Phe content compared with simultaneously obtained blood Phe levels determined on the amino acid analyzer. This comparison was obtained in 5 normal non-PKU persons, 4 carriers of the gene causing PKU, and in 29 individuals with the proven form of the disorder.
RESULTS: Blood-brain measurements in 5 normal persons ranged from.051 to.081 mmol/L, with a mean of.058 mmol/L. Their simultaneously measured brain levels of Phe ranged from.002 to.15 mmol/L, with a mean of.09 mmol/L. Similar measurements were obtained in 4 carriers of the gene causing PKU. Their blood levels varied between.068 and.109 mmol/L, with a mean of.091 mmol/L and simultaneously obtained brain levels of Phe varied between.06 and.21 mmol/L, with a mean of.11 mmol/L. Twenty subjects with a mean IQ of 104 exhibited a mean blood level of 1.428 mmol/L and a simultaneous mean brain level of.23 mmol/L, whereas 9 persons with a mean IQ of 98.7 exhibited a mean blood Phe level of 1.424 and a mean brain Phe level of.64 mmol/L. The correlation between blood and brain levels was not significant.
CONCLUSION: In usual cases, intellectually normal persons who have never been treated but who have a biochemical profile consistent with classical PKU exhibit lower brain levels of Phe. Such individuals are exceptional and may not need the vigorous restriction of their blood Phe levels that is required by the majority of persons with PKU.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11061780     DOI: 10.1542/peds.106.5.1093

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  17 in total

Review 1.  Rare diseases and the assessment of intervention: what sorts of clinical trials can we use?

Authors:  B Wilcken
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

2.  Phenylketonuria in adulthood: a collaborative study.

Authors:  R Koch; B Burton; G Hoganson; R Peterson; W Rhead; B Rouse; R Scott; J Wolff; A M Stern; F Guttler; M Nelson; F de la Cruz; J Coldwell; R Erbe; M T Geraghty; C Shear; J Thomas; C Azen
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

Review 3.  Biological and social influences on cognitive control processes dependent on prefrontal cortex.

Authors:  Adele Diamond
Journal:  Prog Brain Res       Date:  2011       Impact factor: 2.453

4.  Clinical therapeutics for phenylketonuria.

Authors:  Jaspreet Singh Kochhar; Sui Yung Chan; Pei Shi Ong; Lifeng Kang
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

5.  MR imaging-based volumetry in patients with early-treated phenylketonuria.

Authors:  Nadine H Pfaendner; Gitta Reuner; Joachim Pietz; Gregor Jost; Dietz Rating; Vincent A Magnotta; Alexander Mohr; Bodo Kress; Klaus Sartor; Stefan Hähnel
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

Review 6.  Nutritional management of PKU with glycomacropeptide from cheese whey.

Authors:  D M Ney; S T Gleason; S C van Calcar; E L MacLeod; K L Nelson; M R Etzel; G M Rice; J A Wolff
Journal:  J Inherit Metab Dis       Date:  2008-10-29       Impact factor: 4.982

7.  Biochemical correlates of neuropsychiatric illness in maple syrup urine disease.

Authors:  Emilie R Muelly; Gregory J Moore; Scott C Bunce; Julie Mack; Don C Bigler; D Holmes Morton; Kevin A Strauss
Journal:  J Clin Invest       Date:  2013-03-08       Impact factor: 14.808

8.  Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria.

Authors:  J Weglage; D Wiedermann; J Denecke; R Feldmann; H G Koch; K Ullrich; H E Möller
Journal:  J Inherit Metab Dis       Date:  2002-10       Impact factor: 4.982

9.  1H MR chemical shift imaging detection of phenylalanine in patients suffering from phenylketonuria (PKU).

Authors:  Paul E Sijens; Matthijs Oudkerk; Dirk-Jan Reijngoud; Klaas L Leenders; Harold W de Valk; Francjan J van Spronsen
Journal:  Eur Radiol       Date:  2004-08-03       Impact factor: 5.315

10.  Brain MRI diffusion-weighted imaging in patients with classical phenylketonuria.

Authors:  Renzo Manara; Alessandro P Burlina; Valentina Citton; Mario Ermani; Francesco Vespignani; Carla Carollo; Alberto B Burlina
Journal:  Neuroradiology       Date:  2009-08-04       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.